The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer
Open accessAbstract
BACKGROUND: Multiparametric magnetic resonance imaging (MRI), with or without MRI-targeted biopsy, is an alternative test to systematic transrectal ultrasonography-guided biopsy in men suspected of having prostate cancer. At present, evidence on which test to use is insufficient to inform detailed evidence-based decision-making. OBJECTIVES: To determine the diagnostic accuracy of the index tests MRI only, MRI-targeted biopsy, the MRI pathway (MRI with or without MRI-targeted biopsy) and systematic biopsy as compared to template-guided biopsy as the reference standard in detecting clinically significant prostate cancer as the target condition, defined as International Society of Urological Pathology (ISUP) grade 2 or higher. Secondary target conditions were the detection of grade 1 and grade 3 or higher-grade prostate cancer, and a potential change in the number of biopsy procedures. SEARCH METHODS: We performed a comprehensive systematic literature search up to 31 July 2018. We searched CENTRAL, MEDLINE, Embase, eight other databases and one trials register. SELECTION CRITERIA: We considered for inclusion any cross-sectional study if it investigated one or more index tests verified by the reference standard, or if it investigated the agreement between the MRI pathway and systematic biopsy, both performed in the same men. We included only studies on men who were biopsy naïve or who previously had a negative biopsy (or a mix of both). Studies involving MRI had to report on both MRI-positive and MRI-negative men. All studies had to report on the primary target condition. DATA COLLECTION AND ANALYSIS: Two reviewers independently extracted data and assessed the risk of bias using the QUADAS-2 tool. To estimate test accuracy, we calculated sensitivity and specificity using the bivariate model. To estimate agreement between the MRI pathway and systematic biopsy, we synthesised detection ratios by performing random-effects meta-analyses. To estimate the proportions of participants with prostate cancer detected by only one of the index tests, we used random-effects multinomial or binary logistic regression models. For the main comparisions, we assessed the certainty of evidence using GRADE. MAIN RESULTS: The test accuracy analyses included 18 studies overall.MRI compared to template-guided biopsy: Based on a pooled sensitivity of 0.91 (95% confidence interval (CI): 0.83 to 0.95; 12 studies; low certainty of evidence) and a pooled specificity of 0.37 (95% CI: 0.29 to 0.46; 12 studies; low certainty of evidence) using a baseline prevalence of 30%, MRI may result in 273 (95% CI: 249 to 285) true positives, 441 false positives (95% CI: 378 to 497), 259 true negatives (95% CI: 203 to 322) and 27 (95% CI: 15 to 51) false negatives per 1000 men. We downgraded the certainty of evidence for study limitations and inconsistency.MRI-targeted biopsy compared to template-guided biopsy: Based on a pooled sensitivity of 0.80 (95% CI: 0.69 to 0.87; 8 studies; low certainty of evidence) and a pooled specificity of 0.94 (95% CI: 0.90 to 0.97; 8 studies; low certainty of evidence) using a baseline prevalence of 30%, MRI-targeted biopsy may result in 240 (95% CI: 207 to 261) true positives, 42 (95% CI: 21 to 70) false positives, 658 (95% CI: 630 to 679) true negatives and 60 (95% CI: 39 to 93) false negatives per 1000 men. We downgraded the certainty of evidence for study limitations and inconsistency.The MRI pathway compared to template-guided biopsy: Based on a pooled sensitivity of 0.72 (95% CI: 0.60 to 0.82; 8 studies; low certainty of evidence) and a pooled specificity of 0.96 (95% CI: 0.94 to 0.98; 8 studies; low certainty of evidence) using a baseline prevalence of 30%, the MRI pathway may result in 216 (95% CI: 180 to 246) true positives, 28 (95% CI: 14 to 42) false positives, 672 (95% CI: 658 to 686) true negatives and 84 (95% CI: 54 to 120) false negatives per 1000 men. We downgraded the certainty of evidence for study limitations, inconsistency and imprecision.Systemic biopsy compared to template-guided biopsy: Based on a pooled sensitivity of 0.63 (95% CI: 0.19 to 0.93; 4 studies; low certainty of evidence) and a pooled specificity of 1.00 (95% CI: 0.91 to 1.00; 4 studies; low certainty of evidence) using a baseline prevalence of 30%, systematic biopsy may result in 189 (95% CI: 57 to 279) true positives, 0 (95% CI: 0 to 63) false positives, 700 (95% CI: 637 to 700) true negatives and 111 (95% CI: 21 to 243) false negatives per 1000 men. We downgraded the certainty of evidence for study limitations and inconsistency.Agreement analyses: In a mixed population of both biopsy-naïve and prior-negative biopsy men comparing the MRI pathway to systematic biopsy, we found a pooled detection ratio of 1.12 (95% CI: 1.02 to 1.23; 25 studies). We found pooled detection ratios of 1.44 (95% CI 1.19 to 1.75; 10 studies) in prior-negative biopsy men and 1.05 (95% CI: 0.95 to 1.16; 20 studies) in biopsy-naïve men. AUTHORS' CONCLUSIONS: Among
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M. G., Sterne, J. A. C., Bossuyt, P. M. M., & the QUADAS-2 Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-8-201110180-00009 · Cited by 14,199
Kamangar, F., Dores, G. M., & Anderson, W. F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.2308 · Cited by 3,434
Ahmed, H. U., El-Shater Bosaily, A., Brown, L. C., Gabe, R., Kaplan, R., Parmar, M. K., Collaco-Moraes, Y., Ward, K., Hindley, R. G., Freeman, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32401-1 · Cited by 3,284
Epstein, J. I., Egevad, L., Amin, M. B., Delahunt, B., Srigley, J. R., & Humphrey, P. A. (2016) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000530 · Cited by 3,236
Mottet, N., Bellmunt, J., Bolla, M., Briers, E., Cumberbatch, M. G., De Santis, M., Fossati, N., Gross, T., Henry, A. M., Joniau, S., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.08.003 · Cited by 3,227
Self-citationMRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis
Kasivisvanathan, V., Rannikko, A. S., Borghi, M., Panebianco, V., Mynderse, L. A., Vaarala, M. H., Briganti, A., Budäus, L., Hellawell, G., Hindley, R. G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801993 · Cited by 3,091
Self-citationPI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2
Weinreb, J. C., Barentsz, J. O., Choyke, P. L., Cornud, F., Haider, M. A., Macura, K. J., Margolis, D., Schnall, M. D., Shtern, F., Tempany, C. M., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.08.052 · Cited by 2,951
Deeks, J. J., Macaskill, P., & Irwig, L. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.01.016 · Cited by 2,910
STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration
Cohen, J. F., Korevaar, D. A., Altman, D. G., Bruns, D. E., Gatsonis, C. A., Hooft, L., Irwig, L., Levine, D., Reitsma, J. B., de Vet, H. C. W., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-012799 · Cited by 2,570
ESUR prostate MR guidelines 2012
Barentsz, J. O., Richenberg, J., Clements, R., Choyke, P., Verma, S., Villeirs, G., Rouviere, O., Logager, V., & Fütterer, J. J. (2012) · European Radiology · doi:10.1007/s00330-011-2377-y · Cited by 2,438
De-duplication of database search results for systematic reviews in EndNote
Bramer, W. M., Giustini, D., de Jonge, G. B., Holland, L., & Bekhuis, T. (2016) · Journal of the Medical Library Association : JMLA · doi:10.3163/1536-5050.104.3.014 · Cited by 2,103
Djavan, B., Waldert, M., Zlotta, A. R., Dobroński, P., Seitz, C., Mesut Remzi, A., BORKOWSKI, A., Schulman, C., & Marberger, M. (2001) · The Journal of Urology · doi:10.1016/s0022-5347(05)65851-x · Cited by 2,048
Grading quality of evidence and strength of recommendations for diagnostic tests and strategies
Schünemann, H. J., Oxman, A. D., Brozek, J., Glasziou, P., Jaeschke, R., Vist, G. E., Williams, J. W., Kunz, R., Craig, J., Montori, V. M., et al. (2008) · BMJ · doi:10.1136/bmj.39500.677199.ae · Cited by 1,782
International Variation in Prostate Cancer Incidence and Mortality Rates
Center, M. M., Jemal, A., Lortet-Tieulent, J., Ward, E., Ferlay, J., Brawley, O., & Bray, F. (2012) · European Urology · doi:10.1016/j.eururo.2012.02.054 · Cited by 1,521
Siddiqui, M. M., Rais-Bahrami, S., Turkbey, B., George, A. K., Rothwax, J., Shakir, N., Okoro, C., Raskolnikov, D., Parnes, H. L., Linehan, W. M., et al. (2015) · JAMA · doi:10.1001/jama.2014.17942 · Cited by 1,505
Early Detection of Prostate Cancer: AUA Guideline
Carter, H. B., Albertsen, P. C., Barry, M. J., Etzioni, R., Freedland, S. J., Greene, K. L., Holmberg, L., Kantoff, P., Konety, B. R., Murad, M. H., et al. (2013) · Journal of Urology · doi:10.1016/j.juro.2013.04.119 · Cited by 1,242
Ilic, D., Neuberger, M. M., Djulbegovic, M., & Dahm, P. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004720.pub3 · Cited by 1,150
Rouvière, O., Puech, P., Renard-Penna, R., Claudon, M., Roy, C., Mège-Lechevallier, F., Decaussin-Petrucci, M., Dubreuil-Chambardel, M., Magaud, L., Remontet, L., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30569-2 · Cited by 1,095
Systematic Review of Complications of Prostate Biopsy
Loeb, S., Vellekoop, A., Ahmed, H. U., Catto, J., Emberton, M., Nam, R., Rosario, D. J., Scattoni, V., & Lotan, Y. (2013) · European Urology · doi:10.1016/j.eururo.2013.05.049 · Cited by 1,073
Fütterer, J. J., Briganti, A., De Visschere, P., Emberton, M., Giannarini, G., Kirkham, A., Taneja, S. S., Thoeny, H., Villeirs, G., & Villers, A. (2015) · European Urology · doi:10.1016/j.eururo.2015.01.013 · Cited by 785
van der Leest, M., Cornel, E., Israël, B., Hendriks, R., Padhani, A. R., Hoogenboom, M., Zamecnik, P., Bakker, D., Setiasti, A. Y., Veltman, J., et al. (2019) · European Urology · doi:10.1016/j.eururo.2018.11.023 · Cited by 777
Dickinson, L., Ahmed, H. U., Allen, C., Barentsz, J. O., Carey, B., Futterer, J. J., Heijmink, S. W., Hoskin, P. J., Kirkham, A., Padhani, A. R., et al. (2011) · European Urology · doi:10.1016/j.eururo.2010.12.009 · Cited by 737
Schoots, I. G., Roobol, M. J., Nieboer, D., Bangma, C. H., Steyerberg, E. W., & Hunink, M. G. M. (2015) · European Urology · doi:10.1016/j.eururo.2014.11.037 · Cited by 687
Self-citationEpstein, J. I., Feng, Z., Trock, B. J., & Pierorazio, P. M. (2012) · European Urology · doi:10.1016/j.eururo.2012.01.050 · Cited by 669
Image-Guided Prostate Biopsy Using Magnetic Resonance Imaging–Derived Targets: A Systematic Review
Moore, C. M., Robertson, N. L., Arsanious, N., Middleton, T., Villers, A., Klotz, L., Taneja, S. S., & Emberton, M. (2013) · European Urology · doi:10.1016/j.eururo.2012.06.004 · Cited by 535
An Update of the Gleason Grading System
Epstein, J. I. (2010) · Journal of Urology · doi:10.1016/j.juro.2009.10.046 · Cited by 533
Pokorny, M. R., de Rooij, M., Duncan, E., Schröder, F. H., Parkinson, R., Barentsz, J. O., & Thompson, L. C. (2014) · European Urology · doi:10.1016/j.eururo.2014.03.002 · Cited by 503
Accuracy of Multiparametric MRI for Prostate Cancer Detection: A Meta-Analysis
de Rooij, M., Hamoen, E. H. J., Fütterer, J. J., Barentsz, J. O., & Rovers, M. M. (2014) · American Journal of Roentgenology · doi:10.2214/ajr.13.11046 · Cited by 470
Valerio, M., Donaldson, I., Emberton, M., Ehdaie, B., Hadaschik, B. A., Marks, L. S., Mozer, P., Rastinehad, A. R., & Ahmed, H. U. (2015) · European Urology · doi:10.1016/j.eururo.2014.10.026 · Cited by 458
Prevalence of incidental prostate cancer: A systematic review of autopsy studies
Bell, K., Mar, C. D., Wright, R. G., Dickinson, J. A., & Glasziou, P. (2015) · International Journal of Cancer · doi:10.1002/ijc.29538 · Cited by 451
Moore, C. M., Kasivisvanathan, V., Eggener, S., Emberton, M., Fütterer, J. J., Gill, I. S., Grubb III, R. L., Hadaschik, B., Klotz, L., Margolis, D. J. A., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.03.030 · Cited by 450
Self-citationWegelin, O., van Melick, H. H. E., Hooft, L., Bosch, J. L. H. R., Reitsma, H. B., Barentsz, J. O., & Somford, D. M. (2017) · European Urology · doi:10.1016/j.eururo.2016.07.041 · Cited by 425
Filson, C. P., Natarajan, S., Margolis, D. J. A., Huang, J., Lieu, P., Dorey, F. J., Reiter, R. E., & Marks, L. S. (2016) · Cancer · doi:10.1002/cncr.29874 · Cited by 406
Moldovan, P. C., Van den Broeck, T., Sylvester, R., Marconi, L., Bellmunt, J., van den Bergh, R. C. N., Bolla, M., Briers, E., Cumberbatch, M. G., Fossati, N., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.02.026 · Cited by 391
Self-citationSonn, G. A., Chang, E., Natarajan, S., Margolis, D. J., Macairan, M., Lieu, P., Huang, J., Dorey, F. J., Reiter, R. E., & Marks, L. S. (2014) · European Urology · doi:10.1016/j.eururo.2013.03.025 · Cited by 371
NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016
Carroll, P. R., Parsons, J. K., Andriole, G., Bahnson, R. R., Castle, E. P., Catalona, W. J., Dahl, D. M., Davis, J. W., Epstein, J. I., Etzioni, R. B., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0060 · Cited by 342
Guidelines for Reporting of Statistics for Clinical Research in Urology
Assel, M., Sjoberg, D., Elders, A., Wang, X., Huo, D., Botchway, A., Delfino, K., Fan, Y., Zhao, Z., Koyama, T., et al. (2019) · European Urology · doi:10.1016/j.eururo.2018.12.014 · Cited by 335
Hamoen, E. H. J., de Rooij, M., Witjes, J. A., Barentsz, J. O., & Rovers, M. M. (2015) · European Urology · doi:10.1016/j.eururo.2014.10.033 · Cited by 316
Padhani, A. R., Weinreb, J., Rosenkrantz, A. B., Villeirs, G., Turkbey, B., & Barentsz, J. (2019) · European Urology · doi:10.1016/j.eururo.2018.05.035 · Cited by 288
Wolters, T., Roobol, M. J., van Leeuwen, P. J., van den Bergh, R. C. N., Hoedemaeker, R. F., van Leenders, G. J. L. H., Schröder, F. H., & van der Kwast, T. H. (2011) · Journal of Urology · doi:10.1016/j.juro.2010.08.082 · Cited by 280
Self-citationDelongchamps, N. B., Peyromaure, M., Schull, A., Beuvon, F., Bouazza, N., Flam, T., Zerbib, M., Muradyan, N., Legman, P., & Cornud, F. (2013) · Journal of Urology · doi:10.1016/j.juro.2012.08.195 · Cited by 275
Moore, C. M., Giganti, F., Albertsen, P., Allen, C., Bangma, C., Briganti, A., Carroll, P., Haider, M., Kasivisvanathan, V., Kirkham, A., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.06.011 · Cited by 270
Self-citationde Rooij, M., Crienen, S., Witjes, J. A., Barentsz, J. O., Rovers, M. M., & Grutters, J. P. C. (2014) · European Urology · doi:10.1016/j.eururo.2013.12.012 · Cited by 198
Goto, Y., Ohori, M., Arakawa, A., Kattan, M. W., Wheeler, T. M., & Scardino, P. T. (1996) · Journal of Urology · doi:10.1016/s0022-5347(01)65702-1 · Cited by 197
Radtke, J. P., Wiesenfarth, M., Kesch, C. V., Freitag, M. T., Alt, C. D., Celik, K., Distler, F. A., Roth, W., Wieczorek, K. S., Stock, C., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.03.039 · Cited by 193
Boesen, L., Nørgaard, N., Løgager, V., Balslev, I., Bisbjerg, R., Thestrup, K.-C., Winther, M. D., Jakobsen, H., & Thomsen, H. S. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.0219 · Cited by 191
Kuru, T. H., Roethke, M. C., Seidenader, J., Simpfendörfer, T., Boxler, S., Alammar, K., Rieker, P., Popeneciu, V. I., Roth, W., Pahernik, S., et al. (2013) · Journal of Urology · doi:10.1016/j.juro.2013.04.043 · Cited by 188
Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next?
Panebianco, V., Barchetti, G., Simone, G., Del Monte, M., Ciardi, A., Grompone, M. D., Campa, R., Indino, E. L., Barchetti, F., Sciarra, A., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.03.007 · Cited by 186
A Magnetic Resonance Imaging–Based Prediction Model for Prostate Biopsy Risk Stratification
Mehralivand, S., Shih, J. H., Rais-Bahrami, S., Oto, A., Bednarova, S., Nix, J. W., Thomas, J. V., Gordetsky, J. B., Gaur, S., Harmon, S. A., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5667 · Cited by 178
Woo, S., Suh, C. H., Kim, S. Y., Cho, J. Y., Kim, S. H., & Moon, M. H. (2018) · American Journal of Roentgenology · doi:10.2214/ajr.18.19880 · Cited by 175
Proposed Adjustments to PI-RADS Version 2 Decision Rules: Impact on Prostate Cancer Detection
Rosenkrantz, A. B., Babb, J. S., Taneja, S. S., & Ream, J. M. (2017) · Radiology · doi:10.1148/radiol.2016161124 · Cited by 168
Kuru, T. H., Wadhwa, K., Chang, R. T. M., Echeverria, L. M. C., Roethke, M. C., Polson, A., Rottenberg, G., Koo, B., Lawrence, E. M., Seidenader, J., et al. (2013) · British Journal of Urology · doi:10.1111/bju.12132 · Cited by 158
Abd-Alazeez, M., Ahmed, H. U., Arya, M., et al. (2013) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2013.06.007 · Cited by 132
A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts
Ankerst, D. P., Straubinger, J., Selig, K., Guerrios, L., Hoedt, A. M. D., Hernández, J., Liss, M. A., Leach, R. J., Freedland, S. J., Kattan, M. W., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.05.003 · Cited by 132
Carter, H. B. (2013) · British Journal of Urology · doi:10.1111/bju.12318 · Cited by 127
Gayet, M. C. W., van der Aa, A., Beerlage, H. P., Schrier, B. P., Mulders, P., & Wijkstra, H. (2015) · British Journal of Urology · doi:10.1111/bju.13247 · Cited by 118
Brown, L. C., Ahmed, H. U., Faria, R., Bosaily, A. E., Gabe, R., Kaplan, R. S., Parmar, M., Collaço‐Moraes, Y., Ward, K., Hindley, R. G., et al. (2018) · Health Technology Assessment · doi:10.3310/hta22390 · Cited by 118
Trends in the Incidence of Fatal Prostate Cancer in the United States by Race
Kelly, S. P., Rosenberg, P. S., Anderson, W. F., Andreotti, G., Younes, N., Cleary, S. D., & Cook, M. B. (2016) · European Urology · doi:10.1016/j.eururo.2016.05.011 · Cited by 106
Lamb, S. E., Mistry, D., Alleyne, S., Atherton, N., Brown, D., Copsey, B., Dosanjh, S., Finnegan, S., Fordham, B., Griffiths, F., et al. (2018) · Health Technology Assessment · doi:10.3310/hta22280 · Cited by 98
Hu, Y., Ahmed, H. U., Carter, T. J., Arumainayagam, N., Lecornet, E., Barzell, W. E., Freeman, A., Nevoux, P., Hawkes, D. J., Villers, A. A., et al. (2012) · British Journal of Urology · doi:10.1111/j.1464-410x.2012.10933.x · Cited by 91
Jambor, I., Boström, P. J., Taimen, P., et al. (2017) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.25641 · Cited by 86
Pahwa, S. S., Schiltz, N. K., Ponsky, L. E., Lu, Z., Griswold, M. A., & Gulani, V. (2017) · Radiology · doi:10.1148/radiol.2017162181 · Cited by 85
Foley, R. W., Maweni, R. M., Gorman, L., Murphy, K., Lundon, D., Durkan, G. C., POWER, R. E., O’Brien, F., O’Malley, K. J., Galvin, D., et al. (2016) · British Journal of Urology · doi:10.1111/bju.13437 · Cited by 80
Prostate‐specific antigen‐based prostate cancer screening: Past and future
Alberts, A. R., Schoots, I. G., & Roobol, M. J. (2015) · International Journal of Urology · doi:10.1111/iju.12750 · Cited by 78
Self-citationGrey, A., Chana, M. S., Popert, R., Wolfe, K., Liyanage, S. H., & Acher, P. L. (2014) · British Journal of Urology · doi:10.1111/bju.12862 · Cited by 77
Numao, N., Yoshida, S., Komai, Y., et al. (2013) · The Journal of Urology · doi:10.1016/j.juro.2013.02.3197 · Cited by 77
Barnett, C. L., Davenport, M. S., Montgomery, J. S., Wei, J. T., Montie, J. E., & Denton, B. T. (2018) · British Journal of Urology · doi:10.1111/bju.14151 · Cited by 70
Robertson, N. L., Hu, Y., Ahmed, H. U., Freeman, A., Barratt, D. C., & Emberton, M. (2013) · European Urology · doi:10.1016/j.eururo.2012.12.057 · Cited by 63
Mortezavi, A., Märzendorfer, O., Donati, O. F., Rizzi, G., Rupp, N. J., Wettstein, M. S., Gross, O., Sulser, T., Hermanns, T., & Eberli, D. (2018) · The Journal of Urology · doi:10.1016/j.juro.2018.02.067 · Cited by 61
Biomarkers in Localized Prostate Cancer
Ferro, M., Buonerba, C., Terracciano, D., Lucarelli, G. T., Cosimato, V., Bottero, D., Deliu, V. M., Ditonno, P., Perdonà, S., Riccardo Autorino, B., et al. (2016) · Future Oncology · doi:10.2217/fon.15.318 · Cited by 60
Simmons, L. A. M., Ahmed, H. U., Moore, C. M., Punwani, S., Freeman, A., Hu, Y., Barratt, D. C., Charman, S. C., van der Meulen, J., & Emberton, M. (2013) · Contemporary Clinical Trials · doi:10.1016/j.cct.2013.11.009 · Cited by 51
Jiang, X., Zhu, S., Feng, G., Zhang, Z., Li, C., Li, H., Wang, C., & Xu, Y. H. (2013) · European Urology · doi:10.1016/j.eururo.2013.01.035 · Cited by 43
Simmons, L. A. M., Kanthabalan, A., Ahmed, H. U., Moore, C. M., Punwani, S., Freeman, A., Jameson, C., Hu, Y., Barrett, D. W., Charman, S. C., et al. (2014) · European Urology Supplements · doi:10.1016/s1569-9056(14)60935-0 · Cited by 41
Feletto, E., Bang, A., Cole‐Clark, D., Chalasani, V., Rasiah, K., & Smith, D. P. (2015) · World Journal of Urology · doi:10.1007/s00345-015-1514-7 · Cited by 38
Kim, E. H., Weaver, J. K., Shetty, A. S., Vetter, J. M., Andriole, G. L., & Strope, S. A. (2016) · Urology · doi:10.1016/j.urology.2016.08.074 · Cited by 23
MRI pathway and TRUS-guided biopsy for detecting clinically significant prostate cancer
Drost, F. H., Roobol, M. J., Nieboer, D., Bangma, C. H., Steyerberg, E. W., Hunink, M. G. M., & Schoots, I. G. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012663 · Cited by 7
Self-citation
Cited by
Mottet, N., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.09.042 · Cited by 2,802
Self-citationCornford, P., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Brunckhorst, O., Darraugh, J., Eberli, D., De Meerleer, G., De Santis, M., Farolfi, A., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.03.027 · Cited by 1,246
Self-citationThe Lancet Commission on prostate cancer: planning for the surge in cases
James, N. D., Tannock, I., N'Dow, J., Feng, F., Gillessen, S., Ali, S. A., Trujillo, B., Al-Lazikani, B., Attard, G., Bray, F., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00651-2 · Cited by 738
MRI-Targeted or Standard Biopsy in Prostate Cancer Screening
Eklund, M., Jäderling, F., Discacciati, A., Bergman, M., Annerstedt, M., Aly, M., Glaessgen, A., Carlsson, S., Grönberg, H., & Nordström, T. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100852 · Cited by 400
Drost, F.-J. H., Osses, D., Nieboer, D., Bangma, C. H., Steyerberg, E. W., Roobol, M. J., & Schoots, I. G. (2020) · European Urology · doi:10.1016/j.eururo.2019.06.023 · Cited by 370
Self-citation
Metadata
- Authors
- Drost, F.-J. H., Osses, D. F., Nieboer, D., Steyerberg, E. W., Bangma, C. H., Roobol, M. J., & Schoots, I. G.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2019-04-25
- Volume
- 2019
- Issue
- 4
- Pages
- CD012663-CD012663
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2941679071
- Cited by
- 640
- References
- 77
- FWCI
- 47.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.